Entera Bio Ltd.
(ENTX)
Add Watchlist
2.44 USD 0.00
Closed: 17 May, 3:55 pm
Symbol ENTX
Market Cap 87.3M
Price 2.44
Open 2.60
52-wk High 3.35
50 Day Avg 1.99
Earnings Announcement 2024-08-09
Website https://www.enterabio.com
Name Entera Bio Ltd.
Shares Outstanding 35,785,300
Change % -6.1538%
Low 2.35
52-wk Low 0.52
200 Day Avg 1.07
Last Dividend 0.00
Exchange NASDAQ
Volume 81,665
Previous Close 2.60
High 2.60
EPS -0.28
PE -8.71
Avg Volume 263,266
CUSIP M40527109
Entera Bio Ltd. Outlook
Description Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Currency USD
ISIN IL0011429839
Industry Biotechnology
Changes -0.16
CUSIP M40527109
Range 0.52 - 3.35
Beta 1.64
CIK 0001638097

Entera Bio Ltd. News

16-May-2024 10:41 AM

Are Medical Stocks Lagging Entera Bio (ENTX) This Year?

Here is how Entera Bio Ltd. (ENTX) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.

15-May-2024 8:00 AM

Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

JERUSALEM, May 15, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins, today announced the appointment of Rachel B Wagman, MD, FACE, FACP, as Key Clinical Advisor and Member of its Scientific Advisory Board. Dr. Wagman brings more than 20 years of metabolic bone disease and women's health research and drug development experience to Entera. She has successfully advanced the development of five molecules, including the osteoporosis products teriparatide (Forteo®), denosumab (Prolia®) and romosozumab (Evenity®) through clinical development, registration, and lifecycle management.

13-May-2024 7:00 AM

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that it has been selected to present data for its investigational program EB612 at the Endocrine Society ENDO 2024 Annual Meeting which will be held on June 1-4, 2024 in Boston, Massachusetts.

10-May-2024 4:10 PM

Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates

JERUSALEM, May 10, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended March 31, 2024.

26-Apr-2024 7:06 PM

Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade

The latest trading day saw Entera Bio Ltd. (ENTX) settling at $1.98, representing a -1% change from its previous close.

18-Apr-2024 7:20 PM

Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today

In the closing of the recent trading day, Entera Bio Ltd. (ENTX) stood at $2.24, denoting a +0.9% change from the preceding trading day.

15-Apr-2024 3:43 PM

Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?

Wise investors are placing some biotech stocks on their watchlists this month, as these companies have surged over 160%. With more predicted upside to these companies than we see today, one could book some serious capital appreciation into a portfolio.

12-Apr-2024 10:41 AM

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?

Here is how Entera Bio Ltd. (ENTX) and FibroGen (FGEN) have performed compared to their sector so far this year.

09-Apr-2024 10:11 AM

Here's Why You Should Invest in Entera Bio (ENTX) Stock Now

Here, we discuss some reasons why buying Entera Bio (ENTX) stock now may turn out to be a prudent move.

08-Apr-2024 8:30 AM

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

JERUSALEM, April 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that data from the Phase 2 Trial of its lead clinical compound, EB613 (Oral PTH(1-34) Tablets) for the Treatment of Post-Menopausal Women with Low BMD or Osteoporosis compared to placebo were published in the Journal of Bone and Mineral Research (JBMR).

26-Mar-2024 8:30 AM

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The American Society for Bone and Mineral Research (ASBMR) announced on March 25 2024 that the U.S. Food and Drug Administration (FDA) has communicated to the SABRE (Study to Advance BMD as a Regulatory Endpoint) project team that a ruling to qualify the treatment-related change in bone mineral density (BMD) as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs would be provided within 10 months.